Drug Landscape ›
PARITAPREVIR ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 970
Most-reported reactions
Renal Impairment — 164 reports (16.91%) Drug Interaction — 148 reports (15.26%) Anaemia — 127 reports (13.09%) Fatigue — 96 reports (9.9%) Hyperbilirubinaemia — 88 reports (9.07%) Hepatic Failure — 81 reports (8.35%) Nausea — 76 reports (7.84%) Headache — 69 reports (7.11%) Pruritus — 65 reports (6.7%) Hepatocellular Carcinoma — 56 reports (5.77%)
Source database →
PARITAPREVIR in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is PARITAPREVIR approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for PARITAPREVIR in United States?
Marketing authorisation holder not available in our data.